{
    "clinical_study": {
        "@rank": "11807", 
        "brief_summary": {
            "textblock": "The purpose of this study is to see if it is safe and effective to give one of three\n      different triple-drug combinations to HIV-infected patients who have never been treated with\n      anti-HIV drugs."
        }, 
        "brief_title": "A Study of Three Drug Combination Therapies in HIV-Infected Patients Who Have Never Been Treated With Anti-HIV Drugs", 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "detailed_description": {
            "textblock": "In this open-label, strategic study patients are evaluated at Weeks 0, 1, 2, 4, 8, 12 to\n      Week 48 after being treated on one of the following regimens:\n\n      Stavudine (d4T) + Didanosine (ddI) + Lamivudine (3TC) or d4T + ddI + Indinavir or d4T + ddI\n      + Nevirapine."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Patients must have:\n\n          -  Diagnosed asymptomatic HIV infection.\n\n          -  HIV-1 RNA greater than 500 copies/ml.\n\n          -  CD4+ T-cell count greater than 200/mm3.\n\n          -  Never received antiretroviral therapy.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Excluded:\n\n        Severe non-HIV-related disease.\n\n        Patients with the following prior conditions are excluded:\n\n        History of neuropathy.\n\n        Prior Medication:\n\n        Excluded:\n\n          -  Investigational drug within 1 month prior to study.\n\n          -  Immunomodulatory drug within 1 month prior to study.\n\n        Prior Treatment:\n\n        Excluded:\n\n          -  Radiation therapy within past month.\n\n          -  Chemotherapy within past month."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002407", 
            "org_study_id": "ATLANTIC STUDY"
        }, 
        "intervention": [
            {
                "intervention_name": "Indinavir sulfate", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Nevirapine", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Lamivudine", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Stavudine", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Didanosine", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Didanosine", 
                "Stavudine", 
                "Nevirapine", 
                "Lamivudine", 
                "Indinavir", 
                "Anti-HIV Agents"
            ]
        }, 
        "lastchanged_date": "June 23, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "New York", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "10021"
                }, 
                "name": "Cornell AIDS Clinical Trials Unit"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Randomized Open-Label Strategic Study to Evaluate the Safety and Efficacy of 3 Different Convergent and Divergent Drug Combination Therapies in Anti-Retroviral Naive HIV-1 Infected Patients With CD4+ Counts Above 200/mm3", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "N/A", 
        "reference": [
            {
                "citation": "Katlama C, Murphy R, Johnson V, Squires K, Horban A, Gatell J, Clotet B, Staszewski S, VanLeeuwen R, Clumeck N, Moroni M, Pavia A, Schmidt Au Gonzalez-Lahoz J, Antunes F, Gulick R, Banhegyi D, Montaner J, Calvez V, Sommadossi JP, Lange J. The Atlantic study: a randomised open-label study comparing two protease inhibitors (PI)-sparing antiretroviral strategies versus a standard PI-containing regimen. Conf Retroviruses Opportunistic Infect. 1999 Jan 31-Feb 4;6th:70 (abstract no 18)"
            }, 
            {
                "PMID": "11366117", 
                "citation": "Norton M. Choosing the right initial antiretroviral regimens. GMHC Treat Issues. 1999 Feb;13(2):7-10. No abstract available."
            }, 
            {
                "citation": "Murphy RL, Katlama C, Weverling GJ, et al. Fat redistribution and metabolic changes with a nucleoside-reverse transcriptase inhibitor (NRTI), non-NRTI, or protease inhibitor-based regimen: FRAMS substudy of the Atlantic study. Program and abstracts of the XIV International AIDS Conference; July 7-12, 2002; Barcelona, Spain. Abstract WeOrB1306."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002407"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Weill Medical College of Cornell University", 
                "agency_class": "Other"
            }
        }, 
        "study_design": "Endpoint Classification: Efficacy Study, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 1998"
    }, 
    "geocoordinates": {
        "Cornell AIDS Clinical Trials Unit": "40.714 -74.006"
    }
}